Universal leukoreduction of cellular and plasma components: process control and performance of the leukoreduction process
- 1 June 2001
- journal article
- review article
- Published by Elsevier in Transfusion Clinique et Biologique
- Vol. 8 (3) , 297-302
- https://doi.org/10.1016/s1246-7820(01)00119-7
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Statistical process monitoring of WBC-reduced blood components assessed by two types of softwareTransfusion, 2001
- Detecting failed WBC-reduction processes:computer simulations of intermittent and continuous process failureTransfusion, 2000
- Prestorage versus poststorage white cell reduction for the prevention of the deleterious immunomodulatory effects of allogeneic blood transfusionTransfusion Medicine Reviews, 2000
- New variant Creutzfeldt‐Jakob diseaseand white cell reduction:risk assessment and decision makingin the absence of dataTransfusion, 1999
- Transfusion‐associated immunomodulation and universal white cell reduction: are we putting the cart before the horse?Transfusion, 1999
- New variant Creutzfeldt-Jakob disease (nvCJD): The risk of transmission by blood transfusion and the potential benefit of leukocyte-reduction of blood componentsTransfusion Medicine Reviews, 1999
- Quality Assurance and Standards for Red Cells and PlateletsVox Sanguinis, 1998
- Principles of counting low numbers of leukocytes in leukoreduced blood componentsTransfusion Medicine Reviews, 1997
- Practical guidelines for process validation and process control of white cell‐reduced blood components: report of the Biomedical Excellence for Safer Transfusion (BEST) Working Party of the International Society of Blood Transfusion (ISBT)Transfusion, 1996
- LEUKOCYTE-POOR BLOOD PRODUCTS: FILTRATION MECHANISMSVox Sanguinis, 1994